Video Series

Introduction of expert panelists and treatment guidelines for patients with acne.

Discussion on shared decision making with patients with later stage refractory metastatic colorectal cancer as well as maximizing a patient's quality of life.

Maia Kayal, MD, MS, and Kimberly C. Chen, DO, MSHLM, discuss challenges for biosimilars with interchangeable designation related to automatic substitution in the pharmacy.

Kimberly C. Chen, DO, MSHLM, discusses the potential benefits of interchangeable biosimilars to patients and payers.

John L. Marshall M.D., shares insights on health-related quality of life (HRQoL) findings from SUNLIGHT study presented at ESMO World Congress on Gastrointestinal Cancer (ESMO GI) 2023.

A panel of medical experts discuss the clinical and financial considerations surrounding the treatment of patients diagnosed with schizophrenia.

Social determinants of health impacting the treatment landscape for schizophrenia are discussed.

A panel of experts reviews the emerging interchangeable biosimilars and best practices on how to educate providers and patients on these treatment options.

Maia Kayal, MD, MS, and Jonathan Kay, MD, define interchangeability and review the details of a switching study.

John J. Miller, MD, and Nev Jones, PhD, open a discussion providing an overview on the current state of patients with schizophrenia.

With their final thoughts, the panelists emphasize patient-centered care is at the forefront of critical MS treatment considerations for providers.

A comprehensive look into MS treatment objectives is provided.

Panelists provide their closing thoughts on optimizing the management of HIV.

The panel of experts discusses emerging and anticipated changes to the HIV treatment landscape.

A discussion surrounding clinical trials in multiple sclerosis is led by Dr Haumschild.

The panel expands on the role of BTK inhibitors in the MS treatment landscape.

The panel discusses unmet needs that remain in the treatment and management of HIV.

Dr Welch leads a discussion on collaborations between payers, patients, and providers to optimize the care of patients with HIV.

In their closing thoughts, the panelists provide their key takeaways regarding immunizing against RSV.

BTK inhibitor implementation for MS treatment is explored.

The panelists provide insights into the decision-making process behind switching MS treatment strategies due to lacking or failed therapies.

Key opinion leaders discuss the value of real-world evidence in the management of HIV.

Assessing the quality of an HIV treatment plan is crucial to patient prognosis.

In her closing thoughts, Dr Filer provides insights into the unmet needs in the treatment of RSV.

Discussion surrounding promotion of RSV vaccine awareness is further discussed.

The panel offers strategies for being proactive .

Dr Haumschild leads a discussion surrounding patient and provider collaboration to avoid clinical inertia in MS treatment pathways.

Frontline treatment options and the benefits of early intervention of MS are illustrated.